Verve Therapeutics, Inc. financial data

Symbol
VERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Brookline Avenue, Suite 601, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.64K % +1.24%
Debt-to-equity 27.8 % +14.9%
Return On Equity -35.2 % +5.07%
Return On Assets -27.5 % +7.74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84.6M shares +32.8%
Common Stock, Shares, Outstanding 84.6M shares +36.2%
Entity Public Float 940M USD -99.8%
Common Stock, Value, Issued 85K USD +37.1%
Weighted Average Number of Shares Outstanding, Basic 84.2M shares +36%
Weighted Average Number of Shares Outstanding, Diluted 84.2M shares +36%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 190M USD +13.8%
General and Administrative Expense 52.7M USD +12.1%
Operating Income (Loss) -222M USD -6.5%
Nonoperating Income (Expense) 29.6M USD +80.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -192M USD +7.56%
Income Tax Expense (Benefit) 271K USD -62.5%
Net Income (Loss) Attributable to Parent -193M USD -0.22%
Earnings Per Share, Basic -2.59 USD/shares +18%
Earnings Per Share, Diluted -2.59 USD/shares +18%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 141M USD +102%
Marketable Securities, Current 434M USD +10.7%
Cash, Cash Equivalents, and Short-term Investments 576M USD +24.5%
Assets, Current 591M USD +24.9%
Property, Plant and Equipment, Net 20.2M USD -4.97%
Operating Lease, Right-of-Use Asset 81.7M USD -7.92%
Other Assets, Noncurrent 3.32M USD +171%
Assets 701M USD +19%
Accounts Payable, Current 6.83M USD +117%
Accrued Liabilities, Current 19.8M USD -0.39%
Liabilities, Current 40.4M USD +22.2%
Operating Lease, Liability, Noncurrent 62.2M USD -8.31%
Other Liabilities, Noncurrent 142K USD -39.8%
Liabilities 155M USD +24.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -615K USD +18.4%
Retained Earnings (Accumulated Deficit) -643M USD -42.8%
Stockholders' Equity Attributable to Parent 546M USD +17.4%
Liabilities and Equity 701M USD +19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.1M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 22.7M USD +1016%
Net Cash Provided by (Used in) Investing Activities -41.6M USD -370%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 84.6M shares +36.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62M USD -95.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 146M USD +95.4%
Deferred Tax Assets, Valuation Allowance 172M USD +57%
Deferred Tax Assets, Gross 197M USD +45.1%
Operating Lease, Liability 72.5M USD -6.92%
Depreciation 6.29M USD +53.2%
Payments to Acquire Property, Plant, and Equipment 433K USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -193M USD -0.24%
Lessee, Operating Lease, Liability, to be Paid 101M USD -10.1%
Property, Plant and Equipment, Gross 33.9M USD +18.1%
Operating Lease, Liability, Current 10.3M USD +2.46%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +3.13%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28.2M USD -17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.5M USD +3.14%
Deferred Tax Assets, Operating Loss Carryforwards 51.3M USD +17.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.9M USD +3.15%
Operating Lease, Payments 2.64M USD -16.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 40.1M USD +35.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%